Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

Fausto Roila, Alex Molassiotis, Jørn Herrstedt et al. · Annals of Oncology · 2016 · 580 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin

Hideaki Yahata, Hiroaki Kobayashi, Kenzo Sonoda et al. · International Journal of Clinical Oncology · 2015 · 84 citations

Medicine, Oncology, Pharmacology +16

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial

Cindy Weinstein, Karin Jordan, S.A. Green et al. · Annals of Oncology · 2015 · 82 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy

Yasuhiro Ito, Masato Karayama, Naoki Inui et al. · Lung Cancer · 2014 · 80 citations

Medicine, Oncology, Pharmacotherapy +11

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

Paul J. Hesketh, Ian D. Schnadig, Lee S. Schwartzberg et al. · Cancer · 2016 · 70 citations · Full text

Medicine, Oncology, Pharmacology +17